C. Difficile

>

Latest News

MAD-ID 2025 Highlights Fidaxomicin’s Role in Reducing C difficile Recurrence
MAD-ID 2025 Highlights Fidaxomicin’s Role in Reducing C difficile Recurrence

June 10th 2025

Multiple studies highlight fidaxomicin’s effectiveness across high-risk populations despite cost and access challenges, underscoring the need for education and stewardship to improve guideline adherence.

New Genomic Study Reveals Hidden Pathways of C difficile Transmission in Hospitals
New Genomic Study Reveals Hidden Pathways of C difficile Transmission in Hospitals

April 4th 2025

Investigational Oral Biologic Achieves 100% C difficile Clinical Cure in Preliminary Cohort
Investigational Oral Biologic Achieves 100% C difficile Clinical Cure in Preliminary Cohort

April 3rd 2025

New Meta-Analysis Highlights Most Effective Treatments for Clostridioides difficile Infection
New Meta-Analysis Highlights Most Effective Treatments for Clostridioides difficile Infection

February 6th 2025

Investigational Live Biotherapeutic Product Significantly Reduces Risk of Recurrent Clostridioides difficile
Investigational Live Biotherapeutic Product Significantly Reduces Risk of Recurrent Clostridioides difficile

January 24th 2025

<1
...
2021222324
© 2025 MJH Life Sciences

All rights reserved.